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ABSTRACT  
Purpose of review: Pleural biopsies are often necessary if a pleural effusion remains 
undiagnosed after radiological imaging and pleural fluid analysis.  There are many methods of 
obtaining pleural biopsies, including blind or image-guided procedures, closed-bevel or cutting-
edge needles, and percutaneous or thoracoscopic approaches.  This article will review recent 
research relating to these methods, aiming to provide an overview of the strengths and 
limitations of each technique. 
 
Recent findings: Historically pleural biopsies were undertaken using a blind, closed “Abrams” 
needle method.  However low diagnostic yields and high complication rates are seen with this 
technique compared to newer methods.  Recent research compares image-guided, cutting 
needle approaches to traditional Abrams biopsies, and evaluates the role of medical 
thoracoscopy in comparison to other techniques.   
 
Summary: Thoracoscopic biopsies are the gold standard for investigating pleural disease.  
However this service is not universally available and may be unsuitable for some patients.  
Image-guided cutting-needle biopsies under computed tomography or ultrasound guidance 
have high diagnostic rates and are useful in a wide patient population.  The main role of Abrams 
biopsies is in the diagnosis of tuberculous pleuritis in resource-poor settings.  
 
Keywords: pleura, biopsy, thoracoscopy, image-guided 
 
INTRODUCTION 
Pleural effusions are common, with over 1.5 million people presenting with undiagnosed 
effusions in the US each year [1,2].  There are over 50 recognised causes for pleural effusions, 
and the most common causes vary depending on geographical location and population 
demographics [3, 4].  In Europe and America the commonest aetiologies are heart failure, 
pneumonia and malignancy, whilst in India and Indonesia it is tuberculous pleuritis [5,6].  
 
There are several national guidelines that outline the investigatory pathway for undiagnosed 
effusions [3,7].  Radiological imaging and biochemical analysis of pleural fluid provide initial 
diagnostic information, but histological confirmation is usually required, particularly if 
malignancy is suspected.  Because cytological examination of pleural fluid has a low sensitivity 
for malignant cells (less than 60%), pleural biopsy is often required [3, 8, 9]. 
 
Pleural biopsies can be undertaken percutaneously, using “closed-bevel” needles or cutting-
edge needles.  The procedure can be performed blind, under image-guidance using ultrasound 
or computed tomography (CT), or under direct vision during thoracoscopy.  Thoracoscopy can 
be performed using local anaesthetic and sedation (local anaesthetic thoracoscopy, LAT, also 
sometimes called medical thoracoscopy) or as a surgical procedure (video-assisted 
thoracoscopic surgery, VATS).  The question of which method is optimal has been much 
debated, and over the past 18 months, a number of relevant articles have been published on this 
subject.  These articles will be reviewed here, in the context of pre-existing evidence.      
 
BLIND CLOSED-NEEDLE BIOPSIES 
Percutaneous pleural biopsy was originally described in the 1950s by Abrams and Cope, after 
whom the two original reverse-bevel “closed” needles are named [10, 11].  Abrams needles are 
still used in some countries, as they can be employed at the bedside without imaging.   
Consequently the procedure is inexpensive and relatively straightforward. 
 
However, there are disadvantages to Abrams biopsy.  Complications are not uncommon, 
particularly in the hands of inexperienced practitioners [12]. The most frequent complications 
are pain at the site of biopsy (up to 15%) and pneumothorax (also 15%) [3]. Less common are 
vasovagal symptoms (approximately 5%), haemothorax (less than 2%) or transient fever (less 
than 1%) [3, 12].  Death secondary to haemorrhage has been reported, but this is rare [12]. 
 
The sensitivity of Abrams biopsies for malignancy is between 27% and 60% [12, 13, 14, 15, 16].  
In the largest review of 2893 Abrams samples, diagnostic yield was 57% for malignant disease 
[15].   In people who have had previous thoracentesis with negative cytology, closed pleural 
biopsy may provide additional diagnostic information in up to 12% [8].  This low sensitivity 
reflects the irregular distribution of malignant deposits across the pleura; tumours often cluster 
around the diaphragm and midline, areas that are technically difficult and dangerous to access 
with Abrams needles [3].  The low sensitivity rate, combined with the risk of complications, has 
led to a decrease in the use of Abrams biopsies in suspected malignant pleural effusions. 
 
Abrams biopsies have a higher sensitivity in tuberculous pleural disease.  This is because 
tuberculosis affects the pleura diffusely, thus increasing the probability that an area of disease 
will be sampled during blind biopsies.  The sensitivity for diagnosing tuberculosis with Abrams 
biopsies ranges from 67% to 92% [16, 17, 18, 19, 20*].  Yield is higher if pleural fluid is analysed 
concurrently for lymphocyte count or adenosine deaminase (ADA) [18, 19, 20*].  Pleural fluid or 
tissue culture using liquid media further increases the sensitivity [16, 17].   
 
For this reason, blind pleural biopsies are often used as a first line diagnostic tool in resource-
poor settings, where prevalence of tuberculosis is high [19].  However, outside of this scenario, 
alternative methods are advocated [3].  
 
IMAGE-GUIDED CLOSED-NEEDLE BIOPSIES 
Image guidance can increase the yield of Abrams biopsies and reduce complication rates [21].  
In one randomised trial, patients with exudative effusions who underwent CT-guided Abrams 
biopsy achieved a diagnosis in 87.5% [21].  Complications were few, with one significant bleed 
requiring blood transfusion. 
 
More recently a randomised trial compared medical thoracoscopy with Abrams biopsies taken 
under direct ultrasound vision at a pre-determined site chosen from CT, in patients with 
undiagnosed exudative effusions [22].  Image-guided Abrams biopsy had a diagnostic sensitivity 
of 75%, and this increased to 90% in patients with pleural thickening of greater than 1cm.   This 
compared with an overall diagnostic sensitivity of 85% in the 20 participants who underwent 
medical thoracoscopy.  In people whose pleural thickening was greater than 1cm, medical 
thoracoscopy had a similar diagnostic yield of 90%.  
 
IMAGE-GUIDED CUTTING NEEDLE BIOPSIES 
Cutting needles have been shown to be advantageous to Abrams biopsies with sensitivities of up 
to 88% in observational studies [23, 24, 25].  Cutting needles perform well in the presence of 
pleural thickening, which makes them a useful tool in the diagnosis of malignant pleural 
mesothelioma; a tumour for which pleural fluid cytology has a low yield [25, 26].    
 
The only well-powered, prospective, randomised trial comparing CT-guided cutting needle 
biopsies with Abrams biopsy demonstrated that cutting needle biopsies were 40% more 
sensitive at diagnosing malignancy [27].  The yield from CT-guided biopsy was 87%, compared 
with 47% for Abrams biopsies (p=0.02), with the added benefit of fewer passes of the needle in 
the image-guided group.  The authors conclude that CT-guided pleural biopsy using a cutting 
needle, as shown in Figure 1, should be the preferred method where malignancy is suspected. 
 
This result was replicated in a recent, small randomised trial comparing Abrams biopsy with 
CT-guided biopsy [28*].  This study of 31 patients demonstrated a diagnostic yield of 87.5% 
(14/16) in the CT-guided group, compared with 40% (6/15) in the Abrams group. 
 The accuracy and diagnostic sensitivity of CT-guided biopsies can be increased by using 
“pleural-phase” imaging, in which images are captures at least 60 seconds after the delivery of 
contrast.  This method produces greater pleural enhancement, and clearer visualisation of 
pleural deposits [29]. 
 
Ultrasound-guided pleural biopsies have a similar diagnostic yield to CT-guided biopsies [30].  
The choice of modality is guided by availability and operator preference.  However, ultrasound 
offers specific benefits, including real-time visualisation of needle movement and monitoring of  
movement of the target lesion with respiration.  Ultrasound does not entail exposure to ionising 
radiation, and the equipment is substantially cheaper.  In a retrospective review of 273 biopsies 
of pleural lesions and peripheral lung lesions abutting the pleura, technical success was high 
with both ultrasound and CT guidance (97.1% and 96.5% respectively) [31].  Procedures using 
ultrasound were substantially faster and resulted in fewer negative biopsy results.  There were 
significantly fewer pneumothoraces in the ultrasound group (5.5% vs 14.7%), however the 
relevance of this result is difficult to interpret since participants were not randomised.  
Importantly, information on the incidence of COPD was not collected and this may represent a 
relevant confounding factor in the incidence of iatrogenic pneumothoraces.  
 
Ultrasound-guided cutting needle biopsies can be performed by respiratory physicians, with no 
drop in diagnostic sensitivity [32].  A recent review article suggested that physician-led, 
ultrasound-guided pleural biopsy was effective, both as a planned procedure in patients not 
suitable for thoracoscopy, and as a secondary “on-the-table” option if thoracoscopy failed [33*].  
Diagnoses were obtained in 47 out of 50 patients (94%) of which 46 were correct.  Of 15 
patients with a final diagnosis of malignancy, ultrasound-guided biopsy provided diagnostic 
material in 13 (87%). 
 
As well as guiding the choice of biopsy site, ultrasound can also be used influence technique.  In 
a prospective series of 100 patients, ultrasound was used to assess the extent of pleural disease 
and inform subsequent intervention [34*].  Pleural disease was classified as well-circumscribed 
mass lesions, diffuse pleural thickening/nodularity or insignificant/no pleural thickening, based 
on ultrasound appearance.  In patients with a mass, fine needle aspiration with rapid on-site 
cytological evaluation (ROSE) was undertaken, followed by cutting-needle biopsy if the initial 
diagnosis was non-malignant.  In the presence of pleural thickening biopsies were undertaken, 
using an Abrams needle if the pleura measured 10-24mm or a cutting needle if greater than 
25mm.  If there was no obvious pleural thickening, Abrams biopsy was employed.  This method 
increased the diagnostic yield for malignancy from 31.0% to 89.7% (p<0.001), and for all 
diagnoses to 90%. 
 
These results suggest that when undertaken by experienced operators, image-guided pleural 
biopsies have a high diagnostic sensitivity, and can reliably differentiate between benign and 
malignant disease.   
 
COMPLICATIONS FROM IMAGE-GUIDED BIOPSIES 
Complication rates from image-guided biopsies are low.  In a retrospective analysis of over 500 
acute care hospitals in the US, 79,518 patients were identified who underwent trans-thoracic 
image-guided needle biopsies for cancer.  Of these, 13,091 (16.5%) developed a pneumothorax 
within a month of biopsy and 3,074 (3.9%) required chest tube drainage [35].   
 
Pneumothorax risk may be reduced by injecting saline as the biopsy needle is withdrawn, or by 
rapidly turning the patient onto the side of the biopsy once the procedure is complete [36, 37].  
The use of saline reduced the incidence of pneumothorax to 6.2% compared with 26.1% in the 
control group (p<0.001) [36], whilst the “rapid roll-over” method reduced the incidence of 
pneumothoraces requiring drains, but not the overall incidence of pneumothorax [37].  More 
trials are necessary before these techniques become common practice. 
 
LOCAL ANAESTHESTIC THORACOSCOPY 
Local anaesthetic thoracoscopy (LAT) is a procedure in which a rigid or semi-rigid thoracoscope 
is passed into the pleural cavity via a port inserted by blunt dissection.  The procedure is 
performed under conscious sedation and local anaesthesia, and can take place in a dedicated 
procedure room, bronchoscopy suite or operating theatre [38**].  It allows direct visualisation 
of the pleural surface and targeted sampling of areas of disease (see Figure 2). 
 
A major advantage of LAT over percutaneous biopsies is that both diagnostic and therapeutic 
procedures can be undertaken.  Fluid is drained at the start of the procedure, and a wide-bore 
drain left in place at the end, with associated symptomatic benefit for most patients.   Talc 
poudrage can be performed for pleurodesis at the end of the procedure, provided the pleura 
looks malignant and the lung likely to re-expand.   
 
The diagnostic yield of LAT for pleural malignancy is high.  Pooled results from 22 case series, 
involving 1369 patients, showed an overall diagnostic sensitivity of 92% [39].  LAT is more 
successful at diagnosing malignancy than blind or image-guided Abrams biopsies [22, 40, 41, 
42].  LAT also had a higher diagnostic yield than CT-guided cutting-needle biopsies in one small 
randomised trial [43].   
 
For tuberculous pleuritis the yield with LAT is even higher.  A recent prospective case series 
reported a positive LAT diagnosis of TB in 330 of 333 confirmed cases, giving an overall 
sensitivity of 99.1% [44].  However this study took place in a high prevalence area and may not 
be generalizable.  Additionally the diagnostic criteria for ‘confirmed’ tuberculous pleuritis was 
based on histological parameters alone, which may have increased the apparent sensitivity by 
reducing the denominator population.   
 
However, even taking these interpretive issues into account, LAT biopsies are clearly a reliable 
diagnostic tool for both tuberculous pleuritis and pleural malignancy.  Table 1 summarises the 
diagnostic sensitivity of LAT reported in recent studies. 
 
COMPLICATIONS OF LOCAL ANAESTHETIC THORACOSCOPY 
LAT is generally safe.  In a combined analysis of 47 studies of 4756 patients who underwent 
LAT, mortality was reported in 0.34% of cases, major complications in 1.8% and minor 
complications in 7.8% [39].   Similar rates were reported in recent articles [45, 46, 47].  Table 1 
shows the complication rates of LAT from recent publications.  
 
Potential major complications from LAT include empyema, haemorrhage, pneumonia, tumour 
seeding along procedure tract and bronchopleural fistula causing postoperative pneumothorax 
or prolonged air leak [38**].  Minor complications include subcutaneous emphysema, minor 
bleeding, local wound infection, hypotension during procedure and transient fever. 
 
Table 1 – A summary of the diagnostic yield and complication rates of local anaesthetic 
thoracoscopy reported in recent studies 
 
DISADVANTAGES OF LOCAL ANAESTHETIC THORACOSCOPY 
For LAT, a patient must be able to lie still, in the lateral decubitus position, for a minimum of 30 
minutes.  Joint problems, uncontrollable pain or intractable cough may make the procedure 
impossible due to the risk of movement.  Patients with lung disease who desaturate when lying 
flat are not safe for LAT and patients must be able to maintain adequate oxygen saturations 
during conscious sedation.  Supplementary oxygen may be necessary.  Unfortunately, some 
patients are too frail to tolerate LAT.  
 
LAT requires a pleural effusion of sufficient size into which the introducer port can be safely 
inserted.  In patients with small effusions, an iatrogenic pneumothorax can be induced to allow 
LAT to proceed, although this is associated with a higher risk of complications.  Once the port is 
inserted the lung needs to be able to collapse freely away from the chest wall, therefore patients 
with a highly loculated effusion or tethered lung may not be suitable [38**]. 
 
Unfortunately, access to LAT is not universal, and thoracoscopy is not available in some areas.  
LAT usually requires an overnight in-patient stay (sometimes longer), which puts strain on 
healthcare providers, and may not be acceptable to patients.  Day-case LAT is possible, and is 
becoming more popular, but this requires either the avoidance of talc poudrage or the use of an 
ambulatory pleural catheter on discharge [38**]   
 
Overall, LAT is a safe and well-tolerated procedure with a high diagnostic sensitivity.  Pleural 
biopsy taken at thoracoscopy (LAT or VATS) is considered the gold standard for diagnosing 
pleural malignancy [3].  Access to LAT services, although not universal, is increasing and the 
advent of day-case LAT may improve this further. 
 
VIDEO-ASSISTED THORACOSCOPIC SURGERY (VATS) 
Pleural biopsies taken at VATS carry a sensitivity of 95%, specificity of 100% and negative 
predictive value of 94% [45].  This is similar to LAT, although no randomised trial has directly 
compared the two procedures.  VATS offers the additional benefit of allowing therapeutic 
interventions to be performed at the same time as the diagnostic procedure.  Surgeons are able 
to perform lung resection, tumour de-bulking or talc poudrage during VATS. 
 
However, VATS requires a general anaesthetic, and therefore require a higher degree of physical 
fitness than other biopsy techniques.  Patients with poor performance status are precluded, and 
stronger patients may be unsuitable due to specific co-morbidities such as ischaemic heart 
disease.  Major complications, including bleeding, infection and post-operative air leak have 
been reported in up to 15% of VATS cases [45].  However in a more recent, albeit smaller, audit 
from a UK hospital, a major complication rate of just 1.2% was noted, with minor complications 
occurring in 15.1% [46]. 
 
Due to the invasive nature of VATS, it is generally considered when less aggressive approaches 
(i.e. image-guided biopsy) have failed to provide a diagnosis. 
 
 
NEW DIRECTIONS 
There are a number of new diagnostic techniques under investigation.   Positron-emission 
tomography (PET-CT) can differentiate benign pleural disease from malignant [47].  PET-CT 
may also be a useful tool for identifying potential biopsy sites.  Baseline metabolic activity on 
PET-CT appears to correlate with survival in mesothelioma [48]. 
 
Similarly Magnetic Resonance Imaging (MRI) may have a role in the evaluation of pleural 
disease [48, 49**].  MRI avoids the use of ionising radiation, and can provide both morphological 
and functional information on pleural pathology, as shown in Figure 3.  MRI may be useful for 
targeting pleural biopsies, and can provide information on prognostication and response to 
treatment [49**]. 
 
Cryobiopsy is a new sampling method that uses a cooling probe to ‘freeze’ samples as they are 
taken.  In patients with undiagnosed pleural effusions, cryobiopsies taken during flexi-rigid 
thoracoscopy produced larger samples, with greater preservation of tissue architecture 
compared with standard flexible forceps [50*].  The procedure was safe, with no major 
complications seen, and similar rates of mild, self-limiting bleeding seen following both biopsy 
methods.  The procedure requires deep sedation or general anaesthesia, which be a limitation 
for some patients.  Nonetheless, cryobiopsies are an exciting new diagnostic approach, which 
warrant further investigation in larger randomised trials.    
 
CONCLUSION 
There are different options for obtaining pleural biopsies in undiagnosed pleural effusions.  
Abrams biopsies are associated with low diagnostic yields and significant complications, and 
should be avoided where possible.  However, Abrams biopsies may have a role in resource-poor 
settings with high incidence of tuberculous disease.  Image-guided cutting-needle biopsies using 
ultrasound or CT are straightforward, quick, and associated with high diagnostic sensitivity and 
few complications.  They are an excellent option for people in whom thoracoscopy is not 
possible, or has been attempted and failed.  Thoracoscopy is the gold standard, with diagnostic 
yields over 92% in both medical (local anaesthetic) and surgical procedures.  Thoracoscopy is 
generally safe, but some patients may not be suitable.  Access to medical thoracoscopy is likely 
to increase over the next decade.  New techniques, including day-case thoracoscopy, PET-CT 
and MRI-guided biopsy and cryobiopsies require further research, but may provide alternative 
diagnostic options in the future. 
 
KEY POINTS 
 “Closed” pleural biopsies using Abrams needles should not be performed unless 
resources are limited and likelihood of Tb is high.   
 Image-guided pleural biopsies using cutting-needles have a high diagnostic yield with 
few associated complications. 
 Medical thoracoscopy, if available, is the gold standard for obtaining pleural biopsies, 
with a high sensitivity rates and few complications. 
 Surgical VATS has a high diagnostic yield, but is invasive and only suitable for patients 
with good performance status and few medical co-morbidities. 
 New techniques are being investigated in the diagnosis of pleural disease, including day-
case thoracoscopy, MRI- and PET-CT-guided biopsy, and cryobiopsy. 
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Figure 1 – CT guided biopsy  
The biopsy needle (A) can be seen passing through the chest wall, aiming for a right-sided apical 
lung mass (B). 
Figure 2 – Pleural malignancy seen at local anaesthetic thoracoscopy  
The parietal pleural is inflamed and diffusely infiltrated (A), with discrete, irregular nodular 
tumours clearly visible (B & C).  The collapsed lung can be seen at the bottom of the picture (D), 
lying within a small pool of pleural fluid (E).   
Figure 3 – Thoracic MRI 
Thoracic MRI demonstrating right sided, circumferential pleural thickening with high intensity 
(A) extending over the mediastinum.  This is causing significant restriction and volume loss on 
the right side.  Appearances are consistent with mesothelioma. 
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